276 related articles for article (PubMed ID: 17018631)
1. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Wang H; Han H; Von Hoff DD
Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.
Wang H; Stephens B; Von Hoff DD; Han H
Pancreas; 2009 Jul; 38(5):551-7. PubMed ID: 19276868
[TBL] [Abstract][Full Text] [Related]
3. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.
Grau AM; Zhang L; Wang W; Ruan S; Evans DB; Abbruzzese JL; Zhang W; Chiao PJ
Cancer Res; 1997 Sep; 57(18):3929-34. PubMed ID: 9307274
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.
Hao J; Zhang S; Zhou Y; Hu X; Shao C
FEBS Lett; 2011 Jan; 585(1):207-13. PubMed ID: 21112326
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells.
Glienke W; Maute L; Wicht J; Bergmann L
Eur J Cancer; 2009 Mar; 45(5):874-80. PubMed ID: 19196508
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells.
Youns M; Efferth T; Reichling J; Fellenberg K; Bauer A; Hoheisel JD
Biochem Pharmacol; 2009 Aug; 78(3):273-83. PubMed ID: 19393226
[TBL] [Abstract][Full Text] [Related]
7. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
[TBL] [Abstract][Full Text] [Related]
8. [Alterations in DPC4 gene in pancreatic cancers].
Gu L; Chen J; Cui Q
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):293-5. PubMed ID: 11783110
[TBL] [Abstract][Full Text] [Related]
9. Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines.
Hamada S; Satoh K; Hirota M; Fujibuchi W; Kanno A; Umino J; Ito H; Satoh A; Kikuta K; Kume K; Masamune A; Shimosegawa T
Cancer Sci; 2009 Jan; 100(1):103-10. PubMed ID: 19018761
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.
Reed MF; Zagorski WA; Howington JA; Zilfou JT; Knudsen ES
Ann Thorac Surg; 2006 Jul; 82(1):249-53. PubMed ID: 16798224
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.
Hao J; Zhang S; Zhou Y; Liu C; Hu X; Shao C
Biochem Biophys Res Commun; 2011 Mar; 406(4):552-7. PubMed ID: 21352803
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.
Logsdon CD; Simeone DM; Binkley C; Arumugam T; Greenson JK; Giordano TJ; Misek DE; Kuick R; Hanash S
Cancer Res; 2003 May; 63(10):2649-57. PubMed ID: 12750293
[TBL] [Abstract][Full Text] [Related]
13. [Expression of DPC4/Smad4, p21wafI, and p16 in human pancreatic cancer].
Gu LJ; Chen J; Lu ZH; Li L; Zhou WX; Luo YF
Ai Zheng; 2002 Feb; 21(2):132-7. PubMed ID: 12479060
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors.
Bartsch D; Hahn SA; Danichevski KD; Ramaswamy A; Bastian D; Galehdari H; Barth P; Schmiegel W; Simon B; Rothmund M
Oncogene; 1999 Apr; 18(14):2367-71. PubMed ID: 10327057
[TBL] [Abstract][Full Text] [Related]
15. [The effects of transferring DPC4-adenovirus on pancreatic adenocarcinoma cells].
Feng XL; Zhang ZD; Tian L; Wei YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):607-11. PubMed ID: 15460398
[TBL] [Abstract][Full Text] [Related]
16. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.
Grubbs EG; Abdel-Wahab Z; Tyler DS; Pruitt SK
Ann Surg Oncol; 2006 Dec; 13(12):1645-54. PubMed ID: 16957968
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
18. [Alterations of DPC4/SMAD4/MADH4 gene detected in paraffin-embedded tissues of human pancreatic carcinomas].
Gu LJ; Chen J; Liu TH; Cui QC; Lu ZH; Li L; Gao J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Apr; 24(2):165-9. PubMed ID: 12905795
[TBL] [Abstract][Full Text] [Related]
19. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
20. SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells.
Pang LP; Huang W; Sun Q; Guo W; Li RT; Cui JR
Anticancer Drugs; 2008 Feb; 19(2):167-74. PubMed ID: 18176113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]